drugset / Trial / NCT06508437

Effect of Influenza Vaccination on Global Systemic Inflammatory Markers in Patients With Stable Coronary Artery Disease

NCT06508437

Phase 4 Completed 47 enrolled University Hospital, Tours
RandomizedParallel-groupSingle-blindTreatment

Summary

Observational and randomized studies suggest that influenza vaccine may reduce future cardiovascular events in patients with cardiovascular disease. Beyond classical view of indirect effect, linked to the neutralisation of the virus, it is currently considered whether the vaccination may have a direct effect on inflammatory process.Atherosclerosis is known to be driven both by lipid stress and inflammation both at local and systemic level. The investigators suggest that influenza vaccination could have a positive effect on atherosclerosis by regulating plasma inflammation. The aim of this pilot study is therefore to assess the impact of influenza vaccination in patients with stable coronary artery disease on the circulating inflammatory response, in order to validate its potential immunomodulatory effect. If it is found to be beneficial, it could also constitute a future adjuvant therapeutic tool to traditional pharmacotherapy in the prevention of cardiovascular events.

Timeline

Start
2024-10-21
Primary completion
2024-10-31
Completion
2024-11-25

Drugs

EvaluationDrugModalityDoseRoute
Comparator NITRAMINE Vaccine 15 ug
Comparator NITRAMINE Vaccine 0.5 ml